RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 1.79 million. The enterprise value is 1.07 million.
| Market Cap | 1.79M |
| Enterprise Value | 1.07M |
Important Dates
The last earnings date was Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RAMM Pharma has 119.39 million shares outstanding.
| Current Share Class | 119.39M |
| Shares Outstanding | 119.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.43% |
| Owned by Institutions (%) | 0.01% |
| Float | 81.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.53 |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.12 |
| EV / Sales | 0.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.01.
| Current Ratio | 0.74 |
| Quick Ratio | 0.47 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.63 |
Financial Efficiency
Return on equity (ROE) is -92.17% and return on invested capital (ROIC) is -28.90%.
| Return on Equity (ROE) | -92.17% |
| Return on Assets (ROA) | -21.77% |
| Return on Invested Capital (ROIC) | -28.90% |
| Return on Capital Employed (ROCE) | -79.36% |
| Weighted Average Cost of Capital (WACC) | 17.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.45 |
Taxes
In the past 12 months, RAMM Pharma has paid 15,247 in taxes.
| Income Tax | 15,247 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.00% in the last 52 weeks. The beta is 0.64, so RAMM Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -25.00% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 37.61 |
| Average Volume (20 Days) | 69,484 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 3.36 million and -8.91 million in losses. Loss per share was -0.07.
| Revenue | 3.36M |
| Gross Profit | 848,564 |
| Operating Income | -4.53M |
| Pretax Income | -8.89M |
| Net Income | -8.91M |
| EBITDA | -3.93M |
| EBIT | -4.53M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 803,882 in cash and 80,394 in debt, with a net cash position of 723,488 or 0.01 per share.
| Cash & Cash Equivalents | 803,882 |
| Total Debt | 80,394 |
| Net Cash | 723,488 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 5.70M |
| Book Value Per Share | 0.05 |
| Working Capital | -922,375 |
Cash Flow
| Operating Cash Flow | -1.06M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 601,896 |
| Net Borrowing | -145,487 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 25.25%, with operating and profit margins of -134.83% and -265.13%.
| Gross Margin | 25.25% |
| Operating Margin | -134.83% |
| Pretax Margin | -264.68% |
| Profit Margin | -265.13% |
| EBITDA Margin | -116.92% |
| EBIT Margin | -134.83% |
| FCF Margin | n/a |
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -497.53% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RAMM Pharma has an Altman Z-Score of -12.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.39 |
| Piotroski F-Score | 2 |